Novo Nordisk A/S
Novo Nordisk A/S (NVO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
nvo · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Novo Nordisk A/S (NVO) measures how much investors pay for each dollar of the company's trailing earnings. NVO's current PE ratio of 9.91x is calculated by dividing its stock price of $41.02 by its TTM earnings per share of $27.45. −67.4% discount vs 5Y avg 30.4x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 20 fiscal years · Front-end computedMinQ1 · 25%23.5x
MedianQ3 · 75%38.3x
Max
At 9.91x, NVO's current P/E is lower than in 0% of its annual fiscal year readings over the past 20 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Novo Nordisk A/SYou NVO | $182.3B | 9.91x | -51.2% | $27.45 |
 Abbott Laboratories ABT | $157.6B | 33.55x | +65.4% | $3.73 |
 Amgen Inc. AMGN | $186.6B | 22.84x | +12.6% | $14.33 |
 AstraZeneca PLC AZN | $281.6B | 26.53x | +30.7% | $6.62 |
 Gilead Sciences, Inc. GILD | $159.0B | 17.94x | -11.6% | $6.84 |
 GSK plc GSK | $101.8B | 6.45x | -68.2% | $5.64 |
 Merck & Co., Inc. MRK | $295.2B | 14.43x | -28.9% | $7.30 |
Industry Average 6 peers with valid PE | — | 20.29x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 14.05x | $23.03 | -48.6% | |
2024-12-31 FY2024 | 27.33x | $22.67 | -26.0% | |
2023-12-31 FY2023 | 36.93x | $18.67 | -3.7% | |
2022-12-31 FY2022 | 38.35x | $12.26 | +8.9% | |
2021-12-31 FY2021 | 35.21x | $10.40 | +49.4% | |
2020-12-31 FY2020 | 23.56x | $9.03 | +0.2% | |
2019-12-31 FY2019 | 23.51x | $8.20 | +25.1% | |
2018-12-31 FY2018 | 18.80x | $7.98 | -13.9% | |
2017-12-31 FY2017 | 21.83x | $7.70 | +28.9% | |
2016-12-31 FY2016 | 16.94x | $7.48 | -42.6% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Novo Nordisk A/S (NVO) measures how much investors pay for each dollar of the company's trailing earnings. NVO's current PE ratio of 9.91x is calculated by dividing its stock price of $41.02 by its TTM earnings per share of $27.45.
Frequently asked questions
NVO pe ratio · 6 questionsNVO's current PE ratio is 9.91x as of 2026-06-08, based on a stock price of $41.02 and TTM EPS of $27.45. Data sourced from Financial Modeling Prep via NVO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Novo Nordisk A/S SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08